Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University for Dermatology Treatment Candidate WEG232

Rhea-AI Summary

Hoth Therapeutics (NASDAQ: HOTH) announced an expanded research agreement with George Washington University to investigate WEG232 for treating dermatological side effects related to chemotherapy and immunotherapy. The company aims to request a Pre-IND meeting with the FDA by year-end. WEG232 has shown promise in reducing erlotinib-induced facial rash by approximately 71%. Future studies will explore optimal application timing and its effects on inflammation. CEO Robb Knie expressed optimism about advancing this much-needed therapeutic for cancer patients.

Positive

• Expanded research agreement with George Washington University enhances collaboration.
• WEG232 shows potential with a 71% reduction in erlotinib-induced facial rash.
• Plans to request Pre-IND meeting with FDA signals progress toward regulatory approval.

Negative

• None.

NEW YORK, June 16, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.

The company has increased its commitment to further the science behind this therapeutic with Dr. William Wegliki's lab at GW.  Hoth intends to request a Pre-IND meeting with the FDA by year-end. 

Hoth continues to develop topical WEG232 formulation for treatment of mild to moderate (grades 1-3) rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. A recent research study suggested the topical application of WEG232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity. 

Future studies will include:

• Determining the optimal treatment or pretreatment time of application and the weekly number of applications, eg. 2 or 3/week, of WEG232 to prevent the occurrence of the anticipated skin rash/hair loss.
• Determine at the facial skin level if differentially effective topical applications correlate with the extent of suppressed SP-mediated neurogenic inflammation.
• Determine any impact the topical WEG232 application may have on the indicators of systemic neurogenic inflammation and oxidative stress.

"We are pleased to broaden our relationship with the George Washington University as we continue to make great strides in bringing a much needed therapeutic to patients struggling with the many side effects of chemo and immunotherapy," stated Mr. Robb Knie, CEO of Hoth Therapeutics. 

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

Forward-Looking Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com

KCSA Strategic Communications
Valter Pinto, Managing Director
(212) 896-1254
Hoth@kcsa.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-enters-into-expanded-sponsored-research-agreement-with-the-george-washington-university-for-dermatology-treatment-candidate-weg232-301077812.html

SOURCE Hoth Therapeutics, Inc.

FAQ

What is Hoth Therapeutics planning with WEG232?

Hoth Therapeutics is exploring the use of WEG232 for treating dermatological side effects caused by chemotherapy and immunotherapy.

What type of agreement did Hoth Therapeutics enter with George Washington University?

Hoth Therapeutics expanded its sponsored research agreement with George Washington University to further develop WEG232.

What are the results of the WEG232 study mentioned in the press release?

The study indicated that WEG232 could achieve a 71% reduction in facial rash and hair loss induced by erlotinib.

What are the future plans for WEG232?

Future studies will focus on determining optimal application timing and assessing its impact on inflammation.

When does Hoth Therapeutics plan to meet with the FDA?

Hoth Therapeutics intends to request a Pre-IND meeting with the FDA by the end of the year.